Financial Performance - The company's operating revenue for Q1 2023 was CNY 306,811,212.93, representing a 26.91% increase compared to CNY 241,753,611.42 in the same period last year[4] - Net profit attributable to shareholders for Q1 2023 was CNY 56,826,297.00, a significant increase of 117.82% from CNY 26,088,609.26 in the previous year[4] - Basic and diluted earnings per share for Q1 2023 were CNY 0.3596, up 63.16% from CNY 0.2204 in the previous year[4] - Total operating revenue for Q1 2023 reached CNY 306,811,212.93, an increase of 27% compared to CNY 241,753,611.42 in the same period last year[41] - The net profit for Q1 2023 was CNY 56,230,385.30, a significant increase of 115.5% compared to CNY 26,088,609.26 in Q1 2022[42] - Operating profit reached CNY 77,054,137.71, up from CNY 39,498,037.29, reflecting a growth of 95.1% year-over-year[42] - Total revenue from operating activities was CNY 325,923,079.64, compared to CNY 266,992,813.72 in the previous year, marking a growth of 22%[46] - Total comprehensive income for the period was CNY 56,230,732.85, compared to CNY 26,088,609.26 in the previous year, showing a growth of 115.5%[43] Cash Flow and Investments - The net cash flow from operating activities reached CNY 89,360,198.07, marking a 40.32% increase from CNY 63,683,424.40 in the same period last year[4] - The net cash flow from investing activities for the current period is -35.73 million yuan, a decrease of 168.25% year-on-year, mainly due to increased cash payments for investments and fixed asset acquisitions[28] - The company's cash and cash equivalents at the end of the period were CNY 1,679,507,989.65, down from CNY 1,925,186,152.38 at the end of the previous year[47] Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 2,717,496,458.21, reflecting a 3.11% increase from CNY 2,605,409,436.46 at the end of the previous year[5] - Total liabilities increased to CNY 485,292,632.00 from CNY 459,676,501.22, marking an increase of about 5.5%[38] - The company's total equity as of March 31, 2023, was CNY 2,232,203,826.21, up from CNY 2,175,973,093.36 at the beginning of the year, indicating a growth of approximately 2.6%[39] Expenses - The operating cost for the current period is 162.04 million yuan, an increase of 12.27% year-on-year, attributed to the corresponding increase in costs due to the expansion of the business scale[24] - The income tax expense for the current period is 20.64 million yuan, an increase of 55.08% year-on-year, mainly due to the increase in taxable income resulting from revenue growth[27] - The company's management expenses for the current period are 40.57 million yuan, an increase of 40.03% year-on-year, primarily due to increases in labor costs, software service fees, consulting fees, and rental fees[24] - Sales expenses increased to CNY 33,760,100.39 from CNY 30,579,191.68, reflecting a rise of 7.1%[42] Accounts and Receivables - Accounts receivable increased by 61.61% compared to the end of the previous year, primarily due to an increase in receivables from medical insurance[14] - Accounts receivable increased to CNY 50,874,099.62 from CNY 31,480,161.65, representing a growth of approximately 62%[36] - Contract liabilities surged by 95.71% compared to the end of the previous year, attributed to an increase in advance payments received[19] - Contract liabilities rose to CNY 25,512,937.54 from CNY 13,035,929.20, representing an increase of about 96%[38] Strategic Initiatives - The company plans to continue expanding its market presence and investing in new technologies to enhance service delivery and operational efficiency[34] - The company has implemented a new accounting policy effective January 1, 2023, which has resulted in adjustments to deferred tax assets and liabilities[6] Other Financial Metrics - The company's financial expenses for the current period are -6.69 million yuan, a decrease of 197.24% year-on-year, mainly due to an increase in bank deposit interest[25] - The company's investment income for the current period is 1.28 million yuan, a growth of 100.00% compared to the same period last year, primarily due to increased returns from financial products[26] - Research and development expenses were CNY 165,166.61, indicating a focus on innovation despite overall expense increases[42] - The total number of ordinary shareholders at the end of the reporting period is 10,401[30]
何氏眼科(301103) - 2023 Q1 - 季度财报